Authors

C. Ola Landgren, MD, PhD

Latest:

Dr Landgren on Recent Treatment Paradigm Changes in Multiple Myeloma

C. Ola Landgren, MD, PhD, discusses the rapidly changing treatment paradigm within multiple myeloma.

C. Ola Landgren, MD, PhD, Memorial Sloan Kettering Cancer Center

C. Parker Gibbs

Latest:

Dr. Gibbs on Testing for p16 and p21 in Osteosarcoma

C. Parker Gibbs Jr, MD, discusses how to test for p16 and p21 in patients with osteosarcoma.

C. Parker Gibbs Jr, MD

Latest:

Dr. Gibbs on the Lack of Treatment Options in Sarcoma

C. Parker Gibbs Jr, MD, discusses the lack of treatment options for patients with soft tissue and bone sarcomas.

Caio Max S. Rocha Lima, MD, Gibbs Cancer Center

Caio Rocha Lima, MD, Gibbs Cancer Center

Caitlin Costello, MD

Latest:

CAR T-Cell Therapy in Multiple Myeloma: Role in the Treatment Landscape

A roundtable discussion on the evolving treatment landscape surrounding CAR T-cell therapy in multiple myeloma, with a focus on future directions and the management of adverse events.

Caitlin F. Bell

Latest:

Neoadjuvant and Adjuvant Chemotherapy Considerations for Triple-Negative Breast Cancer

Growing attempts to develop biomarkers to guide therapy within triple-negative breast cancer may lead to more effective regimens or to novel therapeutic targets.

Caitlin May, MD

Latest:

Dr. May on Olaratumab Activity in Pediatric Bone and Soft Tissue Sarcoma

Caitlin May, PhD, postdoctoral research fellowship at Eli Lilly and Company, discusses olaratumab's (Lartruvo) demonstrating anti-tumor activity in models of pediatric bone and soft-tissue sarcoma.

Caitlin May, PhD

Latest:

Preclinical Activity With Olaratumab in Sarcoma

Caitlin May, PhD, postdoctoral research scientist at Eli Lilly and Company, discusses preclinical activity with olaratumab (Lynparza) in pediatric sarcoma models.

Camille C. Gunderson, MD

Latest:

Dr. Gunderson on the Use of PARP Inhibitors in All-Comers With Ovarian Cancer

Camille C. Gunderson, MD, assistant professor of gynecologic oncology, Stephenson Cancer Center, discusses the use of PARP inhibitors in all-comers with ovarian cancer.

Camille N. Abboud, MD, Washington University School of Medicine

Cancer Care

Cancer Care: A Webinar Without Walls Lecture Series

CancerControl Alberta

Candace Haddox, MD

Latest:

Perspectives on the Hematology-Oncology Fellowship Journey

Candace Haddox, MD, and Narjust Duma, MD, address the uncertainty, the victories, and the defeats common in oncology fellowship programs.

Carey Anders, MD

Latest:

Dr. Anders on Navigating the Treatment Landscape of Metastatic TNBC

Carey K. Anders, MD, discusses navigating the treatment landscape of metastatic triple-negative breast cancer.

Carey K. Anders, MD, Duke Cancer Institute

Latest:

Dr. Anders on the Lessons Learned From the OlympiA Trial in BRCA-Mutated Breast Cancer

Carey K. Anders, MD, discusses lessons learned from the phase 3 OlympiA trial in BRCA-mutated breast cancer.

Carina Dolan, PharmD, BCOP

Latest:

Biosimilar Uptake in Oncology Faces Many Hurdles

Carina Dolan, PharmD, BCOP, discusses the factors that impact the successful uptake of biosimilars in the practice of oncology.

Carl Maltese, MD

Latest:

Resection and Reconstruction of a Solitary Sternal Metastasis After Mastectomy for Breast Cancer: A Case Report and Review of the Literature

In May 2005, a 25-year-old female presented to her primary care physician complaining of a newly palpable breast mass that had grown to several centimeters over the course of a few months.